U.S. and European Regulatory Strategies for Asian MedTech Startups

On-demand webinar

Multimedia
Published on:
April 13, 2022

This webinar is part of the free webinar series “Expanding Beyond APAC” launched to discuss the strategies, challenges, and best practices of entering new markets and scaling beyond the Asia Pacific for MedTech companies.  

The webinar series is prepared together with APACMed, Asia Pacific’s regional trade association which represents manufacturers and providers of medical equipment and devices, in-vitro diagnostics, digital health; as well as local associations and other key stakeholders within the medical technology industry. 

The webinar “U.S. and European Regulatory Strategies for Asian MedTech Startups” focused on the U.S. FDA and EU MDR/IVDR regulatory pathways and strategies for medical device startups based in the Asia Pacific. We examined the role of US FDA pre-sub meetings and the pros and cons of 510(k), PMA, De Novo pathways as well as the implications of obtaining EUA and breakthrough designation. We discussed the challenges of the new EU MDR and IVDR regulations and provided tips on how to work with European Notified Bodies.

WHO SHOULD WATCH THIS WEBINAR:

MedTech, digital health and IVD startups, and Small & Medium-sized Enterprises based in the Asia Pacific planning to expand commercially to Europe and North America. 

WHAT YOU WILL LEARN:
  • What are the alternative regulatory pathways and strategies in the U.S.
  • What are the hot topics and how to streamline the submission process in the U.S.
  • What are the EU MDR/IVDR requirements and impact on startups

Meet the speaker

Mary McNamara-Cullinane – Senior Vice President, Regulatory Affairs, Alira Health

Mary McNamara-Cullinane

Mary is an accomplished and experienced regulatory professional, drawing on 25 years of experience in the healthcare and life sciences field. Mary’s clearances include: 510k (abbreviated and special), PMA approvals, IDE approvals, De Novo, 510k submissions for novel medical devices, and 513g requests for classifications. Mary is also a frequent conference speaker and panelist on a range of topics including MedTech, regulatory affairs, and women in healthcare.

Related news

Multimedia September 29, 2022
Regulatory Strategy for Registering Rare Disease Products in the EU
In this webinar we will focus on how to benefit, today and in the future, from the orphan drug program and build a regulatory strategy for successful rare disease product registration(...)
Drug Development Rare Disease Regulatory
Events September 7, 2022
MDIC Annual Patient Forum 2022
We are pleased to share that we will be joining as speakers MDIC Annual Patient Forum 2022 – a key platform for the discussion of how to transform patient engagement throughout the(...)
Clinical Trials MedTech Patient Engagement
Events August 31, 2022
BIOMEDevice 2022
We are excited to share that we will be joining BIOMEDevice 2022 as speakers! This event will bring engineers, business leaders, disruptive companies, and innovative thinkers from the(...)
Investor Relations Medical Devices MedTech
Multimedia August 29, 2022
Webinar Replay: Clinical Trial Management in MedTech & Working with CROs
As a MedTech company, understanding clinical trial management is critical, and working with CROs is part of the journey. Join the webinar to learn about this crucial topic.
Clinical Trial Management CRO MedTech
Events August 23, 2022
MedtechVision 2022
Join us at the MedtechWomen MedtechVision Conference, where we will be presenting a state of the Medtech Industry Report with an overview of the innovation and advancement and much more.
Diagnotics MedTech Patient Centricity
Publications August 4, 2022
White Paper: New European Health Technology Assessment Regulation
In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.
MedTech Regulatory
Publications July 15, 2022
How to leverage registry-based studies to generate high-quality Real-World Evidence
The use of Real-World Evidence (RWE) in regulatory decision making will support the development and application of better medicines.
Real-World Evidence Registry-based studies Regulatory RWE
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.